4-溴甲基-2-氯-1-甲氧基苯 | 320407-92-9

• 物质功能分类: 有机原料
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴甲基-2-氯-1-甲氧基苯
• 中文别名: 3-氯-4-甲氧基溴苄；4-溴甲基-2-氯-1-苯甲醚
• 英文名称: 4-(bromomethyl)-2-chloro-1-methoxybenzene
• 英文别名: 3-chloro-4-methoxybenzyl bromide；4-Bromomethyl-2-chloro-1-methoxybenzene
• CAS: 320407-92-9
• 化学式: C₈H₈BrClO
• mdl: MFCD06858766
• 分子量: 235.508
• InChiKey: BDYJMOYDXJQHFS-UHFFFAOYSA-N

物化性质

• 沸点：
  273.0±25.0 °C(Predicted)
• 密度：
  1.520±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2909309090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P270,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P405,P501
• 危险品运输编号：
  3261
• 危险性描述：
  H302,H314
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromomethyl-2-chloro-1-methoxybenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromomethyl-2-chloro-1-methoxybenzene
CAS number: 320407-92-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8BrClO
Molecular weight: 235.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴甲基-2-氯-1-甲氧基苯 在 溴 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 potassium iodide 、 sodium hydroxide 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 42.08h， 生成 阿伐那非
  参考文献：
  名称：

  AVANAFIL PREPARATION METHOD

  摘要：

  揭示了一种利用胞嘧啶作为起始物质制备阿瓦那非（I）的方法。制备步骤包括：使用胞嘧啶作为原料，使其与侧链3-氯-4-甲氧基苄卤、N-(2-甲基嘧啶)甲酰胺和S-羟甲基吡咯烷发生反应，制备目标产品阿瓦那非（I）。对于这种制备方法，原料容易获得，流程简单、经济、环保，因此该方法符合工业推动的要求。

  公开号：

  US20160075693A1
• 作为产物：
  描述：

  3-氯-4-甲氧基苄醇 在 phosphorus tribromide 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 4-溴甲基-2-氯-1-甲氧基苯
  参考文献：
  名称：

  Imidazopyridinone derivatives and their use as phosphodiesterase inhibitors

  摘要：

  一种化合物（Ia）：其中变量在规范中定义，其前药或其药用可接受盐在治疗心绞痛、高血压等方面有用。

  公开号：

  US06582351B1

文献信息

• [EN] 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'AZÉTIDINE OU DE CYCLOBUTANE 1,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROSTAGLANDINE D SYNTHASE HÉMATOPOÏÉTIQUE (H-PGDS)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018069863A1

  公开（公告）日：2018-04-19

  A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式（I）的化合物，其中R、R1、R2、R3、Y、Y1、a、X和Z的定义如本文所述。本发明的化合物是造血前列腺素D合成酶（H-PGDS）的抑制剂，可用于治疗杜兴氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗相关疾病的方法。
• Thermodynamic Stabilities of Phenonium Ions Based on Bromide-Transfer Equilibria in the Gas Phase
  作者：Mustanir、Masaaki Mishima、Mizue Fujio、Yuho Tsuno

  DOI：10.1246/bcsj.71.1401

  日期：1998.6

  α-cumyl(1-methyl-1-phenylethyl) cation suggested that π-delocalization in the phenonium ion is essentially less effective than through a benzylic π-interaction. On the other hand, the ρ value of −12.6 is distinctly larger than that for the ordinary benzylic carbocation systems, but is comparable to that of the benzenium ion. In addition, it has been found that the r+ value of the phenonium ions in the gas phase

  苯鎓（亚乙基苯鎓）离子和环取代衍生物的热力学稳定性是基于气相中的溴化物转移平衡确定的。已经表明，苯鎓离子比叔丁基阳离子稳定 2.4 kcal mol-1，并且取代基对其稳定性的影响可以与具有 -12.6 的 ρ 值和 r+ 的 Yukawa-Tsuno 方程相关联0.62。r+ 值小于 α-枯基（1-甲基-1-苯乙基）阳离子的单位值表明，苯鎓离子中的 π-离域作用基本上不如通过苄基 π-相互作用有效。另一方面，-12.6 的 ρ 值明显大于普通苄型碳正离子系统的值，但与苯离子相当。此外，已经发现，气相中苯鎓离子的 r+ 值与芳基辅助过程中 2-芳基乙基甲苯磺酸酯的乙酰化过程中的 r+ 值完全一致。这表明 π 的度数...
• GSK-3BETAINHIBITOR
  申请人：Itoh Fumio

  公开号：US20100069381A1

  公开（公告）日：2010-03-18

  For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  为了提供一种含有噁二唑化合物或其盐或其前药的GSK-3β抑制剂，用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种含有由以下式（I）表示的化合物的GSK-3β抑制剂： 其中每个符号如规范中定义，或其盐或其前药。
• [EN] DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE<br/>[FR] INHIBITEURS DE DÉCARBOXYLASE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
  申请人：KINTAI THERAPEUTICS INC

  公开号：WO2020118163A1

  公开（公告）日：2020-06-11

  Provided are inhibitors of pathogenic, bacterial metabolite production and conjugates of the inhibitors. Also provided are pharmaceutical compositions containing the inhibitors or conjugates and methods of using the same.

  提供了抑制病原体、细菌代谢产物生产的抑制剂以及抑制剂的共轭物。还提供了含有抑制剂或共轭物的药物组合物以及使用它们的方法。
• [EN] BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME<br/>[FR] BIOMARQUEURS ASSOCIÉS À LA MALADIE DE PARKINSON ET LEURS MÉTHODES D'UTILISATION
  申请人：SENDA BIOSCIENCES INC

  公开号：WO2021207634A1

  公开（公告）日：2021-10-14

  The present disclosure relates to the treatment of Parkinson's disease. The present disclosure provides, in some embodiments, methods of treating Parkinson's disease in a patient in need thereof. In some embodiments, the methods disclosed herein comprise administering a levodopa therapy based on a patient's biomarker profile. In some embodiments, the levodopa therapy comprises or lacks a tyrosine decarboxylase inhibitor. Therapeutic uses and compositions are also disclosed.

  本公开涉及帕金森病的治疗。本公开提供了一些实施例，用于治疗需要治疗帕金森病的患者的方法。在一些实施例中，本文所披露的方法包括根据患者的生物标志物谱进行左多巴疗法的给药。在一些实施例中，左多巴疗法包括或不包括酪氨酸脱羧酶抑制剂。还披露了治疗用途和组合物。